U.S. stock night trading fluctuations: JP Morgan raises target price, RAPT Therapeutics rises 6.06% in night trading

U.S. Stock Night Market Movements

RAPT Therapeutics rose 6.06% in the night market. According to recent important news:

1. On October 21, JP Morgan raised the target price for RAPT Therapeutics from $13 to $55 and upgraded the rating to Buy. This news drove the stock price up, reflecting market confidence in the company's strategic direction and the market potential of RPT904.

2. On October 20, RAPT Therapeutics announced that its drug RPT904 for the treatment of chronic spontaneous urticaria showed comparable efficacy and safety to Roche and Novartis's Xolair in its Phase II trial in China. This news led to a significant stock price increase of 90%, reaching $55.64.

3. On October 20, RAPT Therapeutics announced positive top-line data from the Phase II trial of RPT904 in collaboration with Shanghai Jieyou Pharmaceutical, planning to advance to Phase III development in China. This progress enhanced investor confidence in the company's immunology pipeline. The biotechnology industry is performing strongly, and market confidence is increasing.

Stocks with High Trading Volume in the Industry

Recursion Pharmaceuticals had a trading volume of $621,700. According to recent key news:

1. On October 21, Recursion Pharmaceuticals CEO Christopher Gibson sold 100,000 shares and converted 120,000 shares of Class B common stock into Class A common stock. This news raised concerns in the market about confidence in the company's internal management, leading to stock price fluctuations.

2. On October 19, Straits Research projected that the AI-driven drug discovery market will grow at an average annual rate of 32% until 2030. This outlook could drive up Recursion Pharmaceuticals' stock price.

3. No significant news recently. The outlook for the AI drug discovery market is optimistic, but caution is needed regarding volatility risks.

Moderna rose 1.03% in the night market. According to recent news:

1. On October 20, it was found that Moderna's mRNA COVID-19 vaccine can enhance cancer immunotherapy. Research results showed that cancer patients who received the COVID-19 vaccine within 100 days after immunotherapy had longer survival times. This discovery drove Moderna's stock price up by over 5%.

2. On October 21, Moderna released clinical research documents regarding its mRNA influenza vaccine, showing its safety and efficacy in adults aged 50 and older. This news further boosted market confidence in Moderna On October 20, analyst Joseph Stringer assigned a "Hold" rating to Moderna based on data from its mRNA-4359 cancer antigen therapy. Although the data initially shows potential, further validation is needed, and the market remains cautious. The biotechnology sector has performed strongly recently, with significant capital inflows.

GRAIL rose 1.25% in after-hours trading. According to recent important news:

1. On October 20, GRAIL announced it raised $325 million through private financing. This move aims to support its commercial activities and reimbursement efforts, and is expected to support the company's operations until 2030 alongside Samsung's $110 million investment. This news drove the stock price up by 23%. Source: Press Release

2. On October 20, GRAIL announced encouraging trial results for its flagship product Galleri. This product is an early cancer detection blood test that is expected to receive FDA approval and be covered by major insurance companies upon commercialization. This news further boosted market confidence. Source: Press Release

3. On October 20, GRAIL reached an agreement with several investors to issue 4,639,543 shares at a price of $70.05 per share, raising funds for company operations. This news drove the stock price up. Source: Press Release The biotechnology sector has performed strongly recently, with significant capital inflows